How do we ensure that the next generation of biotech medicines can be brought to market in a timely way, that they continue to be safe and effective and — of growing importance — are affordable by healthcare funding agencies, and profitable to the companies developing them?…
JUST PUBLISHED: "Standardized and GMP-Ready, Closed-System Processing of Expanded Adipose-Derived Stem Cells Using the Gibco CTS
Rotea System Across 2D and 3D Bioreactor Expansions." Click on the OPEN ACCESS ARTICLES tab below.